Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts: Gene/Protein Disease Symptom Drug Enzyme Compound   Target Concepts: Gene/Protein Disease Symptom Drug Enzyme Compound

---

Query: EC:4.1.2.42 (DTA)
1,693 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

We studied the adsorption of a cationic surfactant, dodecyltrimethylammonium bromide (DTABr), onto laponite in water-methanol and water-DMSO mixtures at 298 K. Adsorption isotherms were determined by potentiometric methods using DTA(+) and Br(-)-selective electrodes. All of the isotherm shapes in the mixture were classical. Activity coefficients were determined for the transfer between water and hydroorganic mixtures. Comparison of the adsorption isotherms obtained for different surfactant chemical potentials showed that at higher concentrations of free surfactant, the aggregation state does not depend on the nature of the surrounding media. A study of the influence of the ionic strength showed that there is a common intersection point in each hydroorganic mixture. This point corresponds to the charge compensation point and depends on the nature of the surrounding medium.
...
PMID:A potentiometric study of the adsorption of a cationic surfactant onto laponite in water-methanol and water-dimethylsulfoxide mixtures. 1288 13

Adsorption of phenthoate and acetochlor onto kaolin, montmorillonite, bentonite clays and respective organoclays prepared by the exchange of quaternary ammonium as tetradecyltrimethyl ammonium bromide(TTAB), dodecyltrimethylammonium bromide (DTAB), and cetylpyridinium chloride (CPC) were studied. The adsorption equilibrium data points were fitted to Freundlich isotherm equations. The adsorption of phenthoate and acetochlor were significantly enhanced by surfactant treatment of the clays. The amount of both pesticides adsorbed per unit mass of organoclay followed the order of TTA-kaolin < TTA-montmorillonite < TTA-bentonite, which is inconsistent with the organic carbon content of the clays. The removal efficiency of organomontmorillonite to treat acetochlor is in the order of CP (C16)-montmorillonite > TTA (C14)-montmorillonite > DTA (C12)-montmorillonite. Phenthoate is adsorbed to greater extent than acetochlor by each adsorbent, which may be due to the higher hydrophobicity of phenthoate, indicating considerable hydrophobic interaction between adsorbent/adsorbate systems.
...
PMID:Adsorption of phenthoate and acetochlor from water by clays and organoclays. 1555 2

A simple and effective method for synthesizing silica hollow spheres is presented. The synthesis utilizes vesicles from oppositely charged surfactants sodium dodecyl sulfate (SDS) and tetrapropylammonium bromide (TPAB) aqueous solution as template for the silica growth. Tetraethyl orthosilicate (TEOS) is added to the vesicular template as a precursor for the silica formation. Ultrasound was employed to accelerate the formation of vesicles template. The morphology of the silica spheres is uniform and well-defined (diameter: 200 nm-5 microm, wall thickness: 50 nm). The product was also characterized by FTIR, TG-DTA, N2 adsorption. TEM images reveal that the spheres have structure stability after calcinations at 550 degrees C.
...
PMID:Synthesis of silica hollow spheres assisted by ultrasound. 1629 99

A new complex [Cu (Thr)(Phen)H2O] SO4 . HO2 x CH3 OH (Thr = DL-Threonine, Phen = o-Phenanthroline), which has not been published, was synthesized and characterized by elemental analysis, IR spectroscopy, and TG-DTA. The interaction of the complex and sperm DNA was studied by electronic absorption and ethidium bromide (EB) fluorescence spectroscopy. The result indicates that the maximal absorption peaks of this complex are red-shifted and the intensity is weakened; At the same time, it can to some extent quench the emission intensity of EB-DNA system. Therefore, the authors come to a conclusion that the interaction of this complex and sperm DNA is intercalation.
...
PMID:[Synthesis and DNA binding spectroscopy studies of Cu(II)-Thr-Phen]. 1637 85

A novel cetyltrimethyl ammonium silver bromide (CTASB) complex has been prepared simply through the reaction of silver nitrate with cetyltrimethyl ammonium bromide (CTAB) in aqueous solution at room temperature by controlling the concentration of CTAB and the molar ratio of CTAB to silver nitrate in the reaction solution, in which halogen in CTAB is used as surfactant counterion. The structure and thermal behavior of cetyltrimethyl ammonium silver bromide have been investigated by using X-ray diffraction (XRD), infrared spectroscopy (IR), X-ray photoelectron spectroscopy (XPS), UV/vis spectroscopy, thermal analysis (TG-DTA), transmission electron microscopy (TEM), and scanning electron microscopy (SEM). The results show that the complex possesses a metastable layered structure. Upon heating the CTASB aqueous dispersion to above 80 degrees C, the structure change of the complex took place and CTAB-capped nanosized silver bromide particles further formed.
...
PMID:A novel cetyltrimethyl ammonium silver bromide complex and silver bromide nanoparticles obtained by the surfactant counterion. 1718 88

Single crystals of bisthiourea cadmium bromide (BTCB), a new metallorganic material crystallizing in orthorhombic system were grown from slow evaporation solution growth. The grown crystals were characterized by X-ray diffraction, FTIR and FT-Raman spectral studies. The crystals were also subjected to TGA/DTA analysis and second harmonic generation test. The transmission characteristics of the crystal was also studied.
...
PMID:Growth, characterization, vibrational spectroscopic and thermal studies of a new metallorganic non-linear optical crystal-Bisthiourea cadmium bromide. 1848 82

Cryogenic transmission electron microscopy (cryoTEM) was used to study the structures formed in mixtures of sodium dodecylsulfate (SDS) and dodecyltrimethylammonium bromide (DTAB) in dilute aqueous solutions with 0-300 mM NaBr. The DTAB mole fraction, X, was in the range 0.2-0.4, limited at 25 degrees C by precipitation of solid DTA-DS at X=0.38 without salt to X=0.25 at 300 mM NaBr. At a total surfactant concentration of 100 mM the samples separated into two liquid phases (the bottom phase birefringent) within a narrow (+/-0.01 mole fraction units) composition range. At the mid-point X varied from 0.32 without salt to 0.22 at 300 mM NaBr. Elemental analysis of C, S, O, and N in the separated phases of a sample with 100 mM NaBr and X=0.26 showed the top phase to contain almost only SDS at a low concentration, 14 mM, and the bottom phase 175 mM total surfactant, with X=0.27. Elemental analysis on samples without added salt gave erratic results, indicating problems in the physical separation of the phases. The cryoTEM survey of the separated phases revealed similar problems. Without salt both phases showed similar structures, whereas the top phase in the sample with added salt was void of structures larger than small micelles. The cryoTEM survey revealed a variety of structures being simultaneously present in most samples. A general trend with increasing X was an evolution from globular micelles, over disks, bands, branched bands transforming into sparse webs, perforated bilayer structures, and finally smooth bilayers. Increasing salt and total surfactant concentrations resulted in the emergence of structures with smaller mean curvature at lower X. Perforated bilayers were found in samples with 100 mM or less of added salt, and usually persisted to DTAB contents where precipitates appeared. The porous bilayers seemed to derive from sparse webs of band-like structures, and the hole size decreased with increasing X and salt concentration. Two types of recurrent structures were noticed: blastula aggregates, seemingly an intermediate structure transforming crumpled bilayers into vesicles of similar size (diameter 400-500 A), observed over a broad range of conditions, and at 100 mM total surfactant concentration and 50 mM added salt or more a type of regular disks with a diameter of 180+/-30 A.
...
PMID:Stomatosomes, blastula vesicles and bilayer disks: morphological richness of structures formed in dilute aqueous mixtures of a cationic and an anionic surfactant. 1905 97

New antimony(III) bromide complexes with the heterocyclic thioamides, thiourea (TU), 2-mercapto-1-methylimidazole (MMI), 2-mercapto-benzimidazole (MBZIM), 2-mercapto-5-methyl-benzimidazole (MMBZIM), 5-ethoxy-2-mercapto-benzimidazole (EtMBZIM), 2-mercapto-3,4,5,6-tetrahydro-pyrimidine (tHPMT), 2-mercaptopyridine (PYT), 2-mercapto-thiazolidine (MTZD), 3-methyl-2-mercaptobenzothiazole (MMBZT), and 2-mercaptopyrimidine (PMTH) of formulas [SbBr(3)(TU)(2)] (1), [SbBr(3)(MMI)(2)] (2), {[SbBr(2)(MBZIM)(4)](+) [Br](-) H(2)O} (3), {[SbBr(2)(mu(2)-Br)(MMBZIM)(2)](2)} (4), {[SbBr(2)(mu(2)-Br)(EtMBZIM)(2)](2) MeOH} (5), {[SbBr(3)(mu(2)-S-tHPMT)(tHPMT)](n)} (6), {[SbBr(2)(mu(2)-Br)(PYT)(2))(n)} (7), {[SbBr(2)(mu(2)-Br)(MTZD)(2)](n)} (8), [SbBr(3)(MMBZT)(2)] (9), and {[SbBr(5)](2-)[(PMTH(2)(+))(2)]} (10) have been synthesized and characterized by elemental analysis, conductivity measurements, FTIR spectroscopy, FT-Raman spectroscopy, TG-DTA analysis, and X-ray powder diffraction. The crystal structures of 3, 4, 5, 6, 7, 8, and 10 were also determined by X-ray diffraction. In 3, four sulfur atoms from thione ligands and two bromide ions form an octahedral (O(h)) cationic [SbS(4)Br(2)](+) species in which the two bromide anions lie at axial positions. A third bromide counteranion neutralizes the whole complex. 4 and 5 are dimers, whereas 6, 7 and 8 are polymers, built up by monomeric units of square pyramidal (SP) geometry around the metal center, which were formed by two sulfur atoms of thioamide ligands and three bromide ions. Finally, 10 is ionic salt containing 1D polymeric network of {[SbBr(5)](2-)}(n) anions and (-)[(PMTH(2)(+))2] counter cations in the lattice. The complexes showed mostly a moderate cytostatic activity against a variety of tumor cell lines.
...
PMID:New antimony(III) bromide complexes with thioamides: synthesis, characterization, and cytostatic properties. 1923 83

New homoleptic aminoalkoxides of gallium(III) and indium(III) of the types M4{(OC2H4)2NMe}6 [M = Ga (1), In (2)] and [Ga{(OC2H4)3N}]n (3), as well as a previously described Ga2(OC2H4NMe2)6 (A) have been prepared by isopropoxo(chloro)-aminoalkoxo exchange reactions and characterised by elemental analyses, FT-IR and 1H NMR spectroscopy. Formation of a star-shaped Ga[Ga{mu-eta3:eta1-(OC2H4)2NMe}2]3 (1.4CHCl3) and a zigzag linear In4{mu-eta3:eta1-(OC2H4)2NMe}6 (2.6CHCl3), as revealed by X-ray single crystal structures, reflects the structural diversity among N-methyldiethanolaminate derivatives. Their hydrolyses in boiling water, either in presence or absence of tetraalkylamonium bromide, have been studied and, for gallium derivatives, compared with similar hydrolytic reactions of Ga(OiPr)3. The hydrolysed products were studied by FT-IR, TG-DTA and XRD techniques. For gallium derivatives, transition from orthorhombic Ga(O)OH phase of as-prepared powder to phase pure rhombohedral- and monoclinic-Ga2O3 occurred at about 500 degrees C and 700 degrees C, respectively, whereas cubic In(OH)3 phase of as-prepared powder of 2 was converted to cubic In2O3 at 250 degrees C. Partial hydrolyses were also performed and evolution of the particle size in solution was recorded by light scattering measurements. Various sol-gel processing parameters such as concentration and hydrolysis ratio (h) were studied in order to stabilise nano-sized colloidal suspensions for access to thin films by spin coating. The N-methyldiethanolamine derivatives 1 and 2 were found to be the most suitable candidates for sol-gel processing. The transparent Ga2O3 and In2O3 films obtained on glass or Si wafers from spin-coating of 1 and 2, respectively, were characterised by SEM, EDX and XRD.
...
PMID:Homoleptic gallium(III) and indium(III) aminoalkoxides as precursors for sol-gel routes to metal oxide nanomaterials. 1931 2

Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the following tables has been retrieved from the Clinical Trials Knowledge Area of Prous Science Integrity, the drug discovery and development portal, http://integrity.prous.com. This issue focuses on the following selection of drugs: AAV1/SERCA2a, Abacavir sulfate/lamivudine, Adalimumab, Aliskiren fumarate, Ambrisentan, Aripiprazole, AT-7519, Atazanavir sulfate, Atomoxetine hydrochloride, Azacitidine, Azelnidipine; Besifloxacin hydrochloride, Bevacizumab, Bioabsorbable everolimus-eluting coronary stent, Bortezomib, Bosentan, Budesonide/formoterol fumarate; CAIV-T, Carisbamate, Casopitant mesylate, Certolizumab pegol, Cetuximab, Ciclesonide, Ciprofloxacin/dexamethasone, CTCE-9908; Dalcetrapib, Darunavir, Deferasirox, Desloratadine, Disitertide, Drotrecogin alfa (activated), DTA-H19, Duloxetine hydrochloride, Dutasteride; Ecogramostim, Efalizumab, Emtricitabine, Eribulin mesilate, Escitalopram oxalate, Eszopiclone, EUR-1008, Everolimus-eluting coronary stent, Exenatide; Fampridine, Fluticasone furoate, Formoterol fumarate/fluticasone propionate, Fosamprenavir calcium, Fulvestrant; Gabapentin enacarbil, GS-7904L; HPV-6/11/16/18, Human Secretin, Hydralazine hydrochloride/isosorbide dinitrate; Imatinib mesylate, Imexon, Inalimarev/Falimarev, Indacaterol, Indacaterol maleate, Inhalable human insulin, Insulin detemir, Insulin glargine, Ixabepilone; L-Alanosine, Lapatinib ditosylate, Lenalidomide, Levocetirizine dihydrochloride, Liraglutide, Lisdexamfetamine mesilate, Lopinavir, Loratadine/montelukast sodium, Lutropin alfa; MeNZB, Mepolizumab, Micafungin sodium, Morphine hydrochloride; Nabiximols, Nikkomycin Z; Olmesartan medoxomil, Omalizumab; Paclitaxel-eluting stent, Pegfilgrastim, Peginterferon alfa-2a, Peginterferon alfa-2b, Perifosine, PF-489791, Plitidepsin, Posaconazole, Pregabalin; QAX-576; Raltegravir potassium, Ramelteon, Rasagiline mesilate, Recombinant human relaxin H2, rhGAD65, Rivaroxaban, Rosuvastatin calcium, Rotigotine; Saxagliptin, SCH-530348, Sirolimus-eluting stent, SLIT-amikacin, Sorafenib, Sotrastaurin, SR-16234, Sulforaphane; Tadalafil, Tanespimycin, Tapentadol hydrochloride, Teriparatide, Tesofensine, Tiotropium bromide, Tipifarnib, Tirapazamine, TMC-207, Tocilizumab, Tolvaptan, Tosedostat, Treprostinil sodium; Ustekinumab; Varespladib methyl, Vicriviroc, Vildagliptin, Vildagliptin/metformin hydrochloride, Volociximab, Voriconazole; Ziconotide, Ziprasidone hydrochloride.
...
PMID:Gateways to clinical trials. 1990 22


1 2 3 4 Next >>

---